Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 1
1999 1
2002 1
2004 2
2005 1
2006 5
2007 2
2008 3
2009 7
2010 3
2011 1
2012 4
2013 2
2014 4
2015 6
2016 6
2017 9
2018 16
2019 10
2020 4
2021 4
2022 9
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Mecasermin.
Keating GM. Keating GM. BioDrugs. 2008;22(3):177-88. doi: 10.2165/00063030-200822030-00004. BioDrugs. 2008. PMID: 18481900 Review.
After 6.5-7.5 years of mecasermin therapy, the mean increase in the height standard deviation score was +1.4. ...Subcutaneous mecasermin was generally well tolerated in children with severe IGF-I deficiency associated with GH insensitivity....
After 6.5-7.5 years of mecasermin therapy, the mean increase in the height standard deviation score was +1.4. ...Subcutaneous meca …
Mecasermin rinfabate.
Kemp SF. Kemp SF. Drugs Today (Barc). 2007 Mar;43(3):149-55. doi: 10.1358/dot.2007.43.3.1079876. Drugs Today (Barc). 2007. PMID: 17380212 Review.
Mecasermin rinfabate, a complex of equimolar amounts of insulin-like growth factor (IGF)-I and its binding protein IGFBP-3, has been approved by the U.S. ...In addition, the serum half-life of unbound rhIGF-I is shorter when administered to patients with growth hormone ins …
Mecasermin rinfabate, a complex of equimolar amounts of insulin-like growth factor (IGF)-I and its binding protein IGFBP-3, has been …
Mecasermin (Increlex): CADTH Reimbursement Recommendation: Indication: For the treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency.
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Feb. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Feb. PMID: 37797116 Free Books & Documents. Review.
Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.
Williams RM, McDonald A, O'Savage M, Dunger DB. Williams RM, et al. Expert Opin Drug Metab Toxicol. 2008 Mar;4(3):311-24. doi: 10.1517/17425255.4.3.311. Expert Opin Drug Metab Toxicol. 2008. PMID: 18363546 Review.
BACKGROUND: Mecasermin rinfabate (iPLEX), comprising rhIGF-I complexed to rhIGFBP-3, was developed in an attempt to prolong the half-life of IGF-I and potentially reduce side effects. ...CONCLUSIONS: The biological effects of Mecasermin rinfabate are largely similar …
BACKGROUND: Mecasermin rinfabate (iPLEX), comprising rhIGF-I complexed to rhIGFBP-3, was developed in an attempt to prolong the half- …
Mecasermin Tercica.
Norman P. Norman P. Curr Opin Investig Drugs. 2006 Apr;7(4):371-80. Curr Opin Investig Drugs. 2006. PMID: 16625824 Review.
Tercica, under license from Genentech, has developed and launched mecasermin, recombinant human insulin-like growth factor-1 (rhIGF-1), for the treatment of growth failure in children with primary IGF deficiency or with growth hormone (GH) gene deletion who have developed …
Tercica, under license from Genentech, has developed and launched mecasermin, recombinant human insulin-like growth factor-1 (rhIGF-1 …
Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
[No authors listed] [No authors listed] Drugs R D. 2005;6(2):120-7. doi: 10.2165/00126839-200506020-00008. Drugs R D. 2005. PMID: 15777106 Review.
The comparative data will be included in the regulatory filing for mecasermin rinfabate. Mecasermin rinfabate was originally licensed to Welfide for Japan. ...This provides Insmed with 7 years of market exclusivity following approval of mecasermin rinfabate f …
The comparative data will be included in the regulatory filing for mecasermin rinfabate. Mecasermin rinfabate was originally l …
Mecasermin in Insulin Receptor-Related Severe Insulin Resistance Syndromes: Case Report and Review of the Literature.
Plamper M, Gohlke B, Schreiner F, Woelfle J. Plamper M, et al. Int J Mol Sci. 2018 Apr 24;19(5):1268. doi: 10.3390/ijms19051268. Int J Mol Sci. 2018. PMID: 29695048 Free PMC article. Review.
Treatment of these cases is challenging, with the majority of DS patients dying within the first two years of life. rhIGF-I (mecasermin) has been reported to improve metabolic control and increase lifespan in DS patients. ...
Treatment of these cases is challenging, with the majority of DS patients dying within the first two years of life. rhIGF-I (mecasermin …
Molecular Signatures of Response to Mecasermin in Children With Rett Syndrome.
Shovlin S, Delepine C, Swanson L, Bach S, Sahin M, Sur M, Kaufmann WE, Tropea D. Shovlin S, et al. Front Neurosci. 2022 May 31;16:868008. doi: 10.3389/fnins.2022.868008. eCollection 2022. Front Neurosci. 2022. PMID: 35712450 Free PMC article.
However, improvements in corresponding clinical trials have not been consistent. A 20-weeks phase I open label trial of mecasermin (recombinant human IGF-1) in children with RTT demonstrated significant improvements in breathing phenotypes. ...Our analyses revealed gene ex …
However, improvements in corresponding clinical trials have not been consistent. A 20-weeks phase I open label trial of mecasermin (r …
94 results